🔎 Trials Near Me

Beranda › Kanker Ovarium › Ohio › Toledo

Uji klinis Kanker Ovarium di Toledo, OH

12 studi untuk Kanker Ovarium mencari peserta di lokasi sekitar Toledo (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Menerima pesertaFase 2
  • Mercy Health - Saint Anne Hospital, Toledo
  • Mercy Health - Perrysburg Hospital, Perrysburg · 8 mi jauhnya
Semua usia · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05564377

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Menerima pesertaFase 1
  • Site 06, Maumee · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07814248

DESTINY-PANTUMOUR04

Menerima pesertaStudi observasional
  • Research Site, Maumee · 9 mi jauhnya
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07124000

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Menerima pesertaFase 3
  • ProMedica Flower Hospital, Sylvania · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07213804

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Menerima pesertaFase 3
  • Promedica Flower Hospital, Sylvania · 9 mi jauhnya
Usia 18 ke atas · Wanita · Diperbarui 15 Sep 2026 · NCT07214779

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Menerima pesertaStudi observasional
  • Toledo Clinic Cancer Center, Toledo
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Menerima pesertaFase 3
  • ProMedica Flower Hospital, Sylvania · 9 mi jauhnya
Usia 18 ke atas · Wanita · Diperbarui 26 Agu 2026 · NCT05281471

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Menerima pesertaFase 1
  • Normunity Investigational Site, Maumee · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07182149

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Menerima peserta
  • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
  • ProMedica Flower Hospital, Sylvania · 9 mi jauhnya
Usia 35 hingga 50 · Wanita · Diperbarui 7 Agu 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Menerima pesertaFase 3
  • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
  • ProMedica Flower Hospital, Sylvania · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06580314

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • Taylor Cancer Research Center, Maumee · 9 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT04657068

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

Menerima pesertaFase 2
  • Taylor Cancer Research Center, Maumee · 9 mi jauhnya
Usia 8 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05503797

Uji klinis Kanker Ovarium di kota lain

Studi lain di Toledo

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.